Evidence map›Paper›PMID 42601061›Full record

Observational studyTherapeutic advances in respiratory disease

Disease burden and eosinophilic phenotype in Chinese patients with moderate-to-severe asthma: Baseline analysis of a prospective, multicenter study (PRESENT).

Li Yu, Jian He, Yuewen Jiang, Gang Wang, Xin Feng, Lixiu Chen, Kewu Huang, Haiyan Wu, Li Zhen, Jie Cao and 2 more

Registry-linked trialAbstract readMulticenter StudyObservational Study
PubMed Full text at PMC Publisher
In one paragraph

Observational study in Therapeutic advances in respiratory disease. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06422663 (A Prospective, Observational, Multicentre Study To Evaluate The Treatment Pattern Of Moderate-to-Severe Asthma Patients In China), which is not on this map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06422663 completednot on this map

A Prospective, Observational, Multicentre Study To Evaluate The Treatment Pattern Of Moderate-to-Severe Asthma Patients In China

TypeobservationalSponsorAstraZenecaRan2024 to 2025Enrolled500ConditionsModerate-to-Severe Asthma
3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Li YuDepartment of Pulmonary and Critical Care Medicine, Tongji Hospital, School of Medicine, Tongji University, Shanghai, China.ORCID 0000-0002-1054-017X
Jian HeDepartment of Pulmonary and Critical Care Medicine, Anning First People's Hospital Affiliated to Kunming University of Science and Technology, Kunming, China.
Yuewen JiangDepartment of Pulmonary and Critical Care Medicine, Qiyang People's Hospital, Yongzhou, China.
Gang WangDepartment of Pulmonary and Critical Care Medicine, West China Hospital of Sichuan University, Chengdu, China.
Xin FengDepartment of Pulmonary and Critical Care Medicine, Nanbu People's Hospital, Nanchong, China.
Lixiu ChenDepartment of Pulmonary and Critical Care Medicine, Zhangjiagang First People's Hospital, Zhangjiagang, China.
Kewu HuangDepartment of Pulmonary and Critical Care Medicine, Beijing Chao-Yang Hospital, Capital Medical University, Beijing, China.
Haiyan WuDepartment of Pulmonary and Critical Care Medicine, The First People's Hospital of Xiaoshan District, Hangzhou, China.
Li ZhenDepartment of Pulmonary and Critical Care Medicine, Dingzhou People's Hospital, Dingzhou, China.
Jie CaoDepartment of Pulmonary and Critical Care Medicine, Tianjin Medical University General Hospital, Tianjin, China.
Zuoyan LiDepartment of Pulmonary and Critical Care Medicine, Liaoning Province Health Industry Group Iron Coal General Hospital, Tieling, China.
Zhongmin QiuDepartment of Pulmonary and Critical Care Medicine, Tongji Hospital, School of Medicine, Tongji University, Shanghai, China.ORCID 0000-0002-6612-7413

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BackgroundAsthma is a common respiratory disease with a high disease burden in China. The patient population with severe asthma remains largely unexplored.ObjectivesTo describe the disease burden, treatment pattern and eosinophilic phenotype of Chinese patients with moderate-to-severe asthma.DesignThis is a retrospective baseline analysis of the real-world, observational, multicenter PRESENT study (NCT06422663).MethodsPatients receiving Global Initiative for Asthma Step 3-5 treatment were categorized into protocol-specified severe asthma (uncontrolled asthma with medium-dose inhaled corticosteroids [ICS], or asthma with high-dose ICS) and moderate asthma subgroups. This baseline analysis reported patient characteristics, disease burden, treatment patterns, eosinophilic phenotype and testing rates of biomarkers at enrolment. Disease burden was assessed by historical asthma exacerbation rate within the past year, Asthma Control Test (ACT) score and lung function.ResultsOf the 498 patients included, 203 (40.8%) were identified as having protocol-specified severe asthma. Notable disease burden was observed, as reflected by the high proportion of patients experiencing asthma exacerbation (severe asthma: 35.0%; moderate asthma: 14.6%), low ACT score (mean [SD]: severe asthma: 17.4 [3.8]; moderate asthma: 20.6 [3.7]) and declined pre-bronchodilator forced expiratory volume in one second (pre-BD FEV

Indexed as

Adrenal Cortex HormonesAnti-Asthmatic AgentsAsthmaEosinophilsLungAdministration, InhalationAdultAgedChinaCost of IllnessDisease ProgressionEast Asian PeopleFemaleHumansMaleMiddle AgedAdrenal Cortex HormonesAnti-Asthmatic AgentsChinadisease burdeneosinophilsreal-worldsevere asthma

Identifiers

PMID42601061
PMCPMC13477533

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.